Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Madrigal Pharmaceuticals reported robust Q2 2025 results, with Rezdiffra net sales reaching $213 million, up 55% quarter-over-quarter and annualizing over $800 million, driven by an increase to over 23,000 patients on therapy and 80% prescriber penetration among top targets. This strong performance is significantly bolstered by a newly issued U.S. patent extending Rezdiffra's protection to February 2045, enhancing its long-term value proposition. Strategically, Madrigal is preparing for a Germany launch in H2 2025, advancing its MAESTRO-NASH OUTCOMES trial for compensated MASH cirrhosis (F4c) with data expected in 2027 to potentially double market opportunity, and has in-licensed an oral GLP-1 for combination therapy, with clinical trials anticipated in H1 2026. The company maintains confidence in Rezdiffra's foundational role in MASH despite anticipated GLP-1 competition, expecting new entrants to expand overall market awareness and treatment.

Analysis

Madrigal Pharmaceuticals reported a significant acceleration in its commercial launch, with Rezdiffra Q2 2025 net sales reaching $213 million, a 55% quarter-over-quarter increase, placing the drug on an annualized run rate exceeding $800 million. This growth is underpinned by strong underlying demand, with the patient base expanding to over 23,000 and prescriber penetration reaching a key milestone of 80% among its 6,000 top targets. The most material development is the issuance of a new U.S. patent extending Rezdiffra's exclusivity to February 2045, a development that fundamentally enhances the drug's long-term value proposition by providing decades of protected revenue. Management is leveraging this extended runway to execute a multi-pronged growth strategy, including an imminent European launch in Germany, advancing the MAESTRO-NASH OUTCOMES trial in compensated MASH cirrhosis (F4c) which could double the market opportunity, and the strategic in-licensing of an oral GLP-1 for a future combination therapy. While anticipating competition from injectable GLP-1s, the company frames Rezdiffra as a durable foundational therapy, citing its consistent efficacy, oral administration, and strong adherence, and notes that approximately 25% of current patients already use it alongside a GLP-1. Financially, the company is well-capitalized following a $500 million non-dilutive credit facility, though it has flagged that gross-to-net discounts are expected to increase in the second half of 2025 as more payer contracts are implemented.

Key Decisions for Investors

• Investors should re-evaluate long-term valuation models to account for the material extension of U.S. patent protection for Rezdiffra to February 2045, which significantly de-risks the terminal value and extends the cash flow runway by over a decade.
• Monitor gross-to-net dynamics closely, as management explicitly guided for the discount to widen in the second half of 2025, which will temper net revenue growth rates despite continued strong underlying patient demand.
• Assess the company's strategic positioning against upcoming GLP-1 competition by tracking real-world combination use, while also monitoring key pipeline catalysts including the European launch trajectory and clinical progress for the newly in-licensed oral GLP-1 combination and the pivotal F4c OUTCOMES trial.